Announcements Trials
Browse Landscape

Phase

Phase NA 30Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 71Paclitaxel 63Cyclophosphamide 56pembrolizumab 53Fulvestrant 42Carboplatin 40Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 19Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Practice Guidelines as Topic × Breast × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡